Abstract:Lyssaviruses are bullet-shaped, single-stranded, negative-sense RNA viruses and the causative agents of the ancient zoonosis rabies. Africa is the likely home to the ancestors of taxa residing within the Genus Lyssavirus , Family Rhabdoviridae . Diverse lyssaviruses are envisioned as co-evolving with bats, as the ultimate reservoirs, over seemingly millions of years. In terms of relative distribution, overt abundance, and resulting progeny, rabies virus is the most successful lyssavirus species today, but for unknown reasons. All mammals are believed to be susceptible to rabies virus infection. Besides reservoirs among the Chiroptera, meso-carnivores also serve as major historical hosts and are represented among the canids, raccoons, skunks, mongooses, and ferret badgers. Perpetuating as a disease of nature with the mammalian central nervous system as niche, host breadth alone precludes any candidacy for true eradication. Despite having the highest case fatality of any infectious disease and a burden in excess of or comparative to other major zoonoses, rabies remains neglected. Once illness appears, no treatment is proven to prevent death. Paradoxically, vaccines were developed more than a century ago, but the clear majority of human cases are unvaccinated. Tens of millions of people are exposed to suspect rabid animals and tens of thousands succumb annually, primarily children in developing countries, where canine rabies is enzootic. Rather than culling animal populations, one of the most cost-effective strategies to curbing human fatalities is the mass vaccination of dogs. Building on considerable progress to date, several complementary actions are needed in the near future, including a more harmonized approach to viral taxonomy, enhanced de-centralized laboratory-based surveillance, focal pathogen discovery and characterization, applied pathobiological research for therapeutics, improved estimates of canine populations at risk, actual production of required vaccines and related biologics, strategies to maximize prevention but minimize unnecessary human prophylaxis, and a long-term, realistic plan for sustained global program support to achieve success in disease control, prevention, and elimination.

Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs

Current status of human rabies prevention: remaining barriers to global biologics accessibility and disease elimination

Update on lyssaviruses and rabies: will past progress play as prologue in the near term towards future elimination?

Rabies Vaccine for Prophylaxis and Treatment of Rabies: A Narrative Review

Novel Approaches to the Prevention and Treatment of Rabies.

Rabies in a postpandemic world: resilient reservoirs, redoubtable riposte, recurrent roadblocks, and resolute recidivism

Advances in rabies prophylaxis and treatment with emphasis on immunoresponse mechanisms

Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies

Rabies – epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review

Management of Rabies in Humans.

Rabies and rabies research: past, present and future

New developments in rabies vaccination

Protection Against CNS-Targeted Rabies Virus Infection is Dependent upon Type-1 Immune Mechanisms Induced by Live-Attenuated Rabies Vaccines

Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies

Research Progress on Neutralizing Epitopes and Antibodies for the Rabies Virus

Alarming Rise in Global Rabies Cases Calls for Urgent Attention: Current Vaccination Status and Suggested Key Countermeasures

A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis

Role of Oral Rabies Vaccines in the Elimination of Dog-Mediated Human Rabies Deaths

Development of Human Monoclonal Antibodies With Broad Reactivity for Rabies Postexposure Prophylaxis

Towards rabies elimination in the Asia-Pacific region: From theory to practice

Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis